Population outcomes of EBRT with LDR brachytherapy boost for intermediate, high-risk prostate cancer

被引：0
|
作者：
Oh, J. [1 ]
Spadinger, I. [2 ]
Lapointe, V. [1 ]
Morris, J. [1 ]
机构：
[1] BC Canc, Radiat Oncol, Vancouver, BC, Canada
[2] BC Canc, Med Phys, Vancouver, BC, Canada
来源：
RADIOTHERAPY AND ONCOLOGY | 2020年 / 152卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD-0670
引用
收藏
页码：S372 / S372
页数：1
相关论文
共 50 条
  • [41] Single-fraction HDR brachytherapy boost in combination to EBRT for prostate cancer
    Huertas, A.
    Blanchard, P.
    Calmels, L.
    Edouard, M.
    Bossi, A.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S710 - S710
  • [42] Improved survival for patients with prostate cancer receiving high-dose-rate brachytherapy boost to EBRT compared with EBRT alone
    Kent, Aaron R.
    Matheson, Bronwyn
    Millar, Jeremy L.
    [J]. BRACHYTHERAPY, 2019, 18 (03) : 313 - 321
  • [43] SBRT as Monotherapy or Boost for Intermediate or High-Risk Prostate Cancer: A Prospective Observational Study
    Hirsch, A.
    Ruffer, J. E.
    Green, L.
    Semanjaku, R.
    Asis, G.
    Kapinos, M.
    Rivelli, A.
    Liu, Y.
    Mohiuddin, M. M.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E279 - E279
  • [44] Outcomes of radical prostatectomies and HDR brachytherapy in patients with intermediate and high risk prostate cancer
    Macek, P.
    Stricker, P.
    Stevens, M.
    Jagavkar, R.
    Chalasani, V.
    Haynes, A. M.
    Matthews, J.
    Brenner, P.
    Golovsky, D.
    Kooner, R.
    O'Neill, G.
    [J]. BJU INTERNATIONAL, 2006, 97 : 3 - 3
  • [45] 8-year observation results in n=1023 patients with low, intermediate and high risk prostate cancer after I-125 LDR brachytherapy ± EBRT ± antihormonal treatment
    Zimmermann, J.
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2011, 187 : 41 - 42
  • [46] Does Brachytherapy Boost Improve Biochemical Control in Intermediate and High-Risk Prostate Cancer Patients Compared to External Beam Radiotherapy Alone?
    Miszczyk, M.
    Jablonska, I.
    Krzysztofiak, T.
    Magrowski, L.
    Majewski, W.
    Suwinski, R.
    Masri, O.
    Ciepal, J.
    Depowska, G.
    Gmerek, M.
    Nowicka, E.
    Wojcieszek, P. A.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E286 - E287
  • [47] Clinical outcomes of whole pelvis radiotherapy and stereotactic body radiotherapy boost for intermediate- and high-risk prostate cancer
    Kim, Hun Jung
    Phak, Jeong Hoon
    Kim, Woo Chul
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (05) : E342 - E347
  • [48] Survival outcomes of dose-escalated external beam radiotherapy (DE-EBRT) versus combined brachytherapy for intermediate- and high-risk prostate cancer using the National Cancer Data Base
    Amini, Arya
    Jackson, Matthew Wayne
    Yeh, Norman
    Waxweiler, Timothy V.
    Jones, Bernard
    Maroni, Paul
    Kavanagh, Brian D.
    Raben, David
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [49] HDR Brachytherapy in the Management of High-Risk Prostate Cancer
    Masson, Susan
    Persad, Raj
    Bahl, Amit
    [J]. ADVANCES IN UROLOGY, 2012, 2012
  • [50] LDR versus HDR brachytherapy boost in prostate cancer patients - a retrospective analysis
    Rodda, S.
    Murray, L.
    Bottomley, D.
    Bownes, P.
    Wilkinson, C.
    Adiotomre, E.
    Al-Qaisieh, B.
    Dugdale, E.
    Hulson, O.
    Mason, J.
    Smith, J.
    Henry, A. M.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S587 - S587
12345